Cefuroxime combats endophthalmitis

Article

It is possible to achieve a lower rate of endophthalmitis with a single injection of cefuroxime at the conclusion of cataract surgery than by using the more traditional subconjunctival/topical regimens, according to Per Montan of the St Erik Eye Hospital, Stockholm, Sweden.

It is possible to achieve a lower rate of endophthalmitis with a single injection of cefuroxime at the conclusion of cataract surgery than by using the more traditional subconjunctival/topical regimens, according to Per Montan of the St Erik Eye Hospital, Stockholm, Sweden.

In 1996, St Erik's analysed the resistance patterns of 55 causative bacteria and found that 51 of these were sensitive to cefuroxime, a second-generation cephalosporin. It was decided to use 1 mg cefuroxime as a bolus injection at the conclusion of cataract extraction. A sharp decline in endophthalmitis was soon noticed and furthermore, the antibiotic proved to be safe in analyses of endothelial cell counts, laser flare measurements and the presence of IgE production.

Nationwide data confirmed these findings and now, 99% of cataract procedures are performed with intracameral cefuroxime. The incidence of endophthalmitis during the period between 2002 and 2004, based on a sample of 224,000 operations, is just 0.04%. For comparison purposes, data collected between 1999 and 2001, showed that, of the 6,800 procedures performed using topical or subconjunctival antibiotics, the incidence of endophthalmitis was 0.22% compared with 0.05% in the 153,000 operations using cefuroxime.

Montan concluded that it is entirely possible to achieve significantly lower rates of endophthalmitis by using cefuroxime than by using more traditional combined regimens.

Ophthalmology Times Europe reporting from the XXIV Congress of the ESCRS, London, 9-13 September, 2006.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.